<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Psychopharmacology (Berl)</journal-id><journal-id journal-id-type="iso-abbrev">Psychopharmacology (Berl.)</journal-id><journal-title-group><journal-title>Psychopharmacology</journal-title></journal-title-group><issn pub-type="ppub">0033-3158</issn><issn pub-type="epub">1432-2072</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29500585</article-id><article-id pub-id-type="pmc">5869943</article-id><article-id pub-id-type="publisher-id">4844</article-id><article-id pub-id-type="doi">10.1007/s00213-018-4844-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group></article-categories><title-group><article-title>Comparing the effects of oxazepam and diazepam in actual highway driving and neurocognitive test performance: a validation study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9798-651X</contrib-id><name><surname>Jongen</surname><given-names>S.</given-names></name><address><phone>+31(0)43 388 1756</phone><email>stefan.jongen@maastrichtuniversity.nl</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Vuurman</surname><given-names>E. F. P. M.</given-names></name><address><phone>+31(0)43 388 1046</phone><email>eric.vuurman@maastrichtuniversity.nl</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Ramaekers</surname><given-names>J. G.</given-names></name><address><phone>+31(0)43 388 1951</phone><email>j.ramaekers@maastrichtuniversity.nl</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Vermeeren</surname><given-names>A.</given-names></name><address><phone>+31(0)43 388 1952</phone><email>a.vermeeren@maastrichtuniversity.nl</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0481 6099</institution-id><institution-id institution-id-type="GRID">grid.5012.6</institution-id><institution>Neuropsychology and Psychopharmacology section, Faculty of Psychology and Neuroscience, </institution><institution>Maastricht University, </institution></institution-wrap>Maastricht, The Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>2</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="ppub"><year>2018</year></pub-date><volume>235</volume><issue>4</issue><fpage>1283</fpage><lpage>1294</lpage><history><date date-type="received"><day>8</day><month>1</month><year>2018</year></date><date date-type="accepted"><day>28</day><month>1</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><sec><title>Objective</title><p id="Par1">Screening of drug-induced performance impairment is needed to provide meaningful information for users and prescribers regarding the impact of drugs on driving. The main objective was to assess the effects of oxazepam 10&#x000a0;mg (OXA10), oxazepam 30&#x000a0;mg (OXA30), and diazepam 10&#x000a0;mg (DIA10) on standard deviation of lateral position (SDLP) in a highway driving test in actual traffic and to determine the ability of eight neurocognitive tests to detect comparable effects.</p></sec><sec><title>Methods</title><p id="Par2">Twenty-three healthy volunteers participated in a four-way double-blind, placebo-controlled, crossover study. The highway driving test was conducted between 4 and 5&#x000a0;h after drug intake. A range of neurocognitive tests was conducted before and after driving, 2 and 6&#x000a0;h post-treatment, respectively.</p></sec><sec><title>Results</title><p id="Par3">Mean SDLP increased by 1.83, 3.03, and 7.57&#x000a0;cm after OXA10, DIA10, and OXA30, respectively. At 2&#x000a0;h post-treatment, all neurocognitive tests, except the useful field of view, showed performance impairment in all active treatments. Effect sizes (ES) were moderate for OXA10, large ES for DIA10, and largest ES for OXA30. Modest correlations were found between changes in SDLP and performance in the attention network test (ANT), the divided attention test (DAT), and the psychomotor vigilance test (PVT).</p></sec><sec><title>Conclusion</title><p id="Par4">OXA10 caused minor, DIA10 moderate, and OXA30 severe driving impairment. No neurocognitive test was both dose dependently sensitive and able to be associated with driving impairment. No neurocognitive test can replace the on-the-road highway driving test.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Oxazepam</kwd><kwd>Diazepam</kwd><kwd>Neurocognitive tests</kwd><kwd>SDLP</kwd><kwd>On-the-road highway driving test</kwd><kwd>Attention</kwd></kwd-group><funding-group><award-group><funding-source><institution>Maastricht University</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag GmbH Germany, part of Springer Nature 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Psychoactive drugs can have side effects, such as sedation and reduced alertness, which can cause driving impairment and increase crash risk (Dassanayake, Michie, Carter, and Jones, <xref ref-type="bibr" rid="CR7">2011</xref>; O&#x02019;Hanlon, Haak, Blaauw, and Riemersma, <xref ref-type="bibr" rid="CR34">1982</xref>; Seppala, Linnoila, and Mattila, <xref ref-type="bibr" rid="CR42">1979</xref>). Screening a drug&#x02019;s potential to impair the ability to operate a motor vehicle is a necessary means to provide meaningful precautions for users and prescribers of medicinal drugs (Food Drug Administration, <xref ref-type="bibr" rid="CR13">2015</xref>; Kay and Logan, <xref ref-type="bibr" rid="CR19">2011</xref>; O&#x02019;Hanlon, <xref ref-type="bibr" rid="CR35">1986</xref>).</p><p id="Par6">Ideally, drug evaluations should follow a tiered approach starting with neurocognitive tests, followed by driving simulators and finally on-the-road tests, as the latter generally have better validity to assess driving impairment (Berghaus and Friedel, <xref ref-type="bibr" rid="CR3">1999</xref>; Alvarez and del R&#x000ed;o, <xref ref-type="bibr" rid="CR1">2002</xref>; Vermeeren, De Gier, and O&#x02019;Hanlon, <xref ref-type="bibr" rid="CR46">1993</xref>; Walsh, Verstraete, Huestis, and M&#x000f8;rland, <xref ref-type="bibr" rid="CR51">2008</xref>). The standardized on-the-road highway driving test used in the Netherlands (O&#x02019;Hanlon, <xref ref-type="bibr" rid="CR32">1984</xref>; Ramaekers, <xref ref-type="bibr" rid="CR37">2003</xref>; Vermeeren, <xref ref-type="bibr" rid="CR45">2004</xref>; Verster and Roth, <xref ref-type="bibr" rid="CR48">2011</xref>) is a sensitive and reliable test to assess drug-induced driving impairment. Standard deviation of lateral position (SDLP), the primary outcome measure, has been shown to be sensitive to the effects of many sedative drugs (Leufkens and Vermeeren, <xref ref-type="bibr" rid="CR22">2014</xref>; O&#x02019;Hanlon and Ramaekers, <xref ref-type="bibr" rid="CR33">1995</xref>; Ramaekers, <xref ref-type="bibr" rid="CR37">2003</xref>; Roth, Eklov, Drake, and Verster, <xref ref-type="bibr" rid="CR40">2014</xref>). In addition, SDLP has high validity to predict crash risk, as alcohol-induced changes in SDLP are highly correlated (<italic>r</italic>&#x02009;=&#x02009;0.99) with alcohol-induced changes in crash risk (Borkenstein et al., <xref ref-type="bibr" rid="CR5">1964</xref>; Owens and Ramaekers, <xref ref-type="bibr" rid="CR36">2009</xref>).</p><p id="Par7">Initial screening of a drug&#x02019;s impairing potential can be conducted with neurocognitive tests as these are generally easy to administer and cost-effective. However, such neurocognitive tests should be validated for drug sensitivity and generalizability to actual driving in order to provide reliable outcome measures (ICADTS, <xref ref-type="bibr" rid="CR15">1999</xref>; Vermeeren, De Gier and O&#x02019;Hanlon, <xref ref-type="bibr" rid="CR46">1993</xref>; Walsh, Verstraete, Huestis, and M&#x000f8;rland, <xref ref-type="bibr" rid="CR51">2008</xref>). A number of neurocognitive tests have been calibrated by several doses of alcohol reaching blood alcohol concentrations (BAC) of 0.2, 0.5, and 0.8&#x000a0;g/L (Jongen, Vuurman, Ramaekers, and Vermeeren, <xref ref-type="bibr" rid="CR17">2014</xref>). Results suggested that of the selected tests, the psychomotor vigilance test (PVT) and the divided attention test (DAT) are most promising as initial screening tests to detect drug-induced impairment. A follow-up study found that the PVT, DAT, and attention network test (ANT) were most sensitive to the effects of one night of sleep deprivation and showed moderate associations with driving impairment as measured with changes in SDLP (Jongen, Perrier, Vuurman, Ramaekers, and Vermeeren, <xref ref-type="bibr" rid="CR18">2015</xref>).</p><p id="Par8">However, sensitive neurocognitive tests to the effects of alcohol or sleep deprivation are not necessarily able to detect impairing effects of medicinal drugs. For example, the impairment profiles of alcohol and benzodiazepines have been found to differ (Kleykamp, Griffiths, and Mintzer, <xref ref-type="bibr" rid="CR20">2010</xref>; Tiplady, Hiroz, Holmes, and Drummond, <xref ref-type="bibr" rid="CR44">2003</xref>). The neurocognitive tests selected for the present study were the psychomotor vigilance test (PVT), critical tracking test (CTT), divided attention test (DAT), attention network test (ANT), digit symbol substitution test (DSST), useful field of view test (UFOV), postural balance test (PBT), and the determination test (DT), because these were previously found to be sensitive to the effects of alcohol or sleep deprivation (Jongen et al. <xref ref-type="bibr" rid="CR17">2014</xref>, <xref ref-type="bibr" rid="CR18">2015</xref>).</p><p id="Par9">The aim of the present study was to assess the sensitivity of a selection of neurocognitive tests to the effects of two medicinal drugs known to impair driving performance, i.e., the benzodiazepines diazepam and oxazepam (Neutel, <xref ref-type="bibr" rid="CR31">1995</xref>; Ray, Fought, and Decker, <xref ref-type="bibr" rid="CR38">1992</xref>). These medicinal drugs were selected because diazepam 10&#x000a0;mg has been recommended as verum for experimental studies assessing the effects of medicinal drugs on driving (Berghaus et al. <xref ref-type="bibr" rid="CR3">1999</xref>). Oxazepam is currently the most frequently prescribed benzodiazepine in many countries (in recommended doses of 10 to 30&#x000a0;mg per day). Recent epidemiological studies have shown that both diazepam and oxazepam are highly prevalent in impaired drivers (e.g., Bezemer et al. <xref ref-type="bibr" rid="CR4">2014</xref>).</p><p id="Par10">Thus, the primary objective of the present study was to validate the sensitivity of a range of neurocognitive tests mentioned above to the effects of oxazepam (10 and 30&#x000a0;mg) and diazepam 10&#x000a0;mg and compare it with driving impairment (i.e., SDLP changes in the highway driving test). Secondary aims were to establish mean performance changes in each neurocognitive test associated with each drug and dose for future reference and to determine correlations between drug-induced performance changes in neurocognitive tests and on-the-road highway driving.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Participants</title><p id="Par11">Twenty-three healthy volunteers (12 males, 11 females) aged between 21 and 50&#x000a0;years were recruited through advertisements in local papers and at the University of Maastricht. Initial screening was based on a medical history questionnaire examined by the medical supervisor. Eligible participants were invited for a physical examination, which included urinalysis, tests for drugs of abuse (amphetamines, benzodiazepines, cannabis, cocaine, 3,4-methylenedioxymethamphetamine, and opiates), and a 12-lead electrocardiogram. The following inclusion criteria had to be met: possession of a valid driving license for 3&#x000a0;years or more, driving experience of at least 5000&#x000a0;km per year on average over the last 3&#x000a0;years, and a body mass index (BMI) between 19 and 29&#x000a0;kg&#x000a0;m<sup>&#x02212;2</sup>. Exclusion criteria included the following: shift work; history of a sleep disorder; extreme morning or evening type as measured with the Morning Evening Questionnaire (MEQ; Horne and Ostberg, <xref ref-type="bibr" rid="CR14">1976</xref>); any history of psychiatric or medical illness; history or current drug or alcohol abuse; current use of psycho-active medication; excessive caffeine use, defined as drinking six or more cups of coffee per day.</p><p id="Par12">The mean (&#x000b1; SD) age of the participants was 36.8 (&#x000b1;&#x02009;9.5) years. The study was conducted in accordance with the code of ethics on human experimentation established by the declaration of Helsinki (1964) and amended in Seoul (2008). All participants were informed about the study&#x02019;s goal, procedures, and potential hazards in writing, and they gave their informed consent in writing. The Medical Ethics Committees of Maastricht University approved the study. Participants received a financial compensation for their participation in the study.</p></sec><sec id="Sec4"><title>Design</title><p id="Par13">The study was conducted according to a 4-way, randomized, double-blind, placebo-controlled, crossover design. The four treatment conditions were single oral doses of oxazepam 10&#x000a0;mg (OXA10), oxazepam 30&#x000a0;mg (OXA30), diazepam 10&#x000a0;mg (DIA10), and placebo (PBO). Order of treatment conditions was balanced over participants by using a William design. Washout periods between treatments were at least 7&#x000a0;days. To reduce order effects of neurocognitive tests, two neurocognitive test sequences were applied and these were balanced over participants.</p></sec><sec id="Sec5"><title>Procedure</title><p id="Par14">Participants were individually trained to perform the behavioral tests prior to the first treatment day. Participants agreed not to use any drugs of abuse or oral medication (except oral contraceptives and paracetamol) during the study. During participation in the study, alcohol intake was not allowed from 24&#x000a0;h prior to each test day until discharge. On treatment days, caffeine intake and smoking were not allowed until discharge.</p><p id="Par15">On treatment days, participants arrived at the testing site at 8.45 or 10.00&#x000a0;h. The Groningen Sleep Quality Scale (Mulder-Hajonides van der Meulen, <xref ref-type="bibr" rid="CR30">1981</xref>) was administered to assess sleep quality, and urine and breathe samples were yielded to assess compliance with use of drugs and alcohol. Four participants were tested on each testing day. Participants ingested a single treatment dose at 9:00 am, 9:05 am, 10:15 am, or 10:20 am. Four hours after drug intake, the standardized highway driving test was conducted. Before and after the driving test, i.e., 2 and 6&#x000a0;h after treatment intake, participants performed two sessions of laboratory testing (session 1 and session 2). Each session consisted of the PVT, CTT, DAT, ANT, DSST, UFOV, PBT, and DT. Before the driving test, a standardized light lunch was served. After completion of session 2 (at 4:00 pm or 5.15 pm), participants were transported home by study personnel. See Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> for a timeline of the study procedures.<fig id="Fig1"><label>Fig. 1</label><caption><p>Timeline of a treatment day. Time points are relative to time of treatment administration</p></caption><graphic xlink:href="213_2018_4844_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec6"><title>Assessment</title><sec id="Sec7"><title>Highway driving test</title><p id="Par16">In the standardized highway driving test (O&#x02019;Hanlon, <xref ref-type="bibr" rid="CR32">1984</xref>; Verster and Roth, <xref ref-type="bibr" rid="CR48">2011</xref>), the participant operates a specially instrumented vehicle for approximately 1&#x000a0;h over a 100-km (61-mile) primary highway circuit (A2 Netherlands, Maastricht-Weert v.v.), accompanied by a licensed driving instructor having access to dual controls. The task of the participant is to maintain a constant speed of 95&#x000a0;km/h (58&#x000a0;m/h) and a steady lateral position between the delineated boundaries of the right traffic lane. The vehicle&#x02019;s speed and lateral position are recorded continuously. These signals are digitized at a rate of 4&#x000a0;Hz and edited off-line to remove data recorded during overtaking maneuvers or disturbances caused by roadway or traffic situations. The remaining data are then used to calculate mean values and standard deviation of lateral position and speed. The primary outcome variable is standard deviation of lateral position (SDLP, in cm) which is a measure of road tracking error or &#x02018;weaving&#x02019;.</p></sec><sec id="Sec8"><title>Psychomotor vigilance test</title><p id="Par17">The psychomotor vigilance test (PVT) is based on a simple reaction time test (Dinges and Powell, <xref ref-type="bibr" rid="CR8">1985</xref>). Dependent variables are mean reaction time (RT in ms) and number of lapses (RT&#x02009;&#x0003e;&#x02009;500&#x000a0;ms). In addition, inverse reaction times (I/RT) were calculated, as it emphasizes slowing in the optimum and intermediate response domain and substantially decreases the contribution of long lapses (Basner and Dinges, <xref ref-type="bibr" rid="CR2">2011</xref>). Test duration is 10&#x000a0;min.</p></sec><sec id="Sec9"><title>Critical tracking task</title><p id="Par18">The critical tracking task (CTT) measures the ability to control an unstable error signal using a joystick in a first-order compensatory tracking task (Jex, McDonnell, and Phatak, <xref ref-type="bibr" rid="CR16">1966</xref>). The frequency of cursor deviations at which the participant loses control is the critical frequency or lambda (&#x003bb;<sub>c</sub> in rad&#x000a0;s&#x002c9;1). Test duration is approximately 3&#x000a0;min.</p></sec><sec id="Sec10"><title>Divided attention task</title><p id="Par19">The divided attention task (DAT) measures the ability to divide attention between two simultaneously performed tasks, a tracking task and a visual target detection task (Moskowitz, <xref ref-type="bibr" rid="CR29">1973</xref>). The primary dependent measures in the respective subtasks are tracking error (in mm) and average reaction time to targets (in ms). Secondary control measures are number of control losses in the tracking task and number of hits in the target detection task. Task duration is 12&#x000a0;min.</p></sec><sec id="Sec11"><title>Digit symbol substitution test</title><p id="Par20">The digit symbol substitution test (DSST) measures processing speed and working memory. A computerized version (McLeod, Griffiths, Bigelow, and Yingling, <xref ref-type="bibr" rid="CR27">1982</xref>) of the original paper-and-pencil test taken from the Wechsler Adults Intelligence Scale was used. The performance measure is the number of digits encoded correctly within 3&#x000a0;min.</p></sec><sec id="Sec12"><title>Attention network test</title><p id="Par21">The attention network test (ANT) is a choice reaction time using different warning cues (no cue, double cue, center cue, spatial cue) and target stimuli (with congruent or incongruent flankers). It provides measures of three functions of attention, i.e., alerting, orienting, and executive attention (Fan, McCandliss, Sommer, Raz, and Posner, <xref ref-type="bibr" rid="CR12">2002</xref>). Dependent variables are total reaction time, alerting effect (i.e., RT no cue&#x02013;RT double cue), orienting effect (RT center cue&#x02013;RT spatial cue), and conflict effect (RT incongruent flankers&#x02013;RT congruent flankers). The test duration is approximately 20&#x000a0;min.</p></sec><sec id="Sec13"><title>Postural balance test</title><p id="Par22">The postural balance test (PBT) is measured by using the AMTI AccuSway System (Advanced Mechanical Technology, Inc., Watertown, MA) force platform. Postural sway is assessed by the area of the 95% confidence ellipse enclosing the center of pressure (A95 in cm<sup>2</sup>). The test is conducted with feet apart at hip&#x02019;s width in two trials of 60&#x000a0;s: one trial with the participants&#x02019; eyes open and one trial with eyes closed.</p></sec><sec id="Sec14"><title>Determination test</title><p id="Par23">The determination test (DT) (Schuhfried, <xref ref-type="bibr" rid="CR41">2005</xref>) is a choice reaction time task measuring resilience of attention and reaction speed under conditions of sensory stress. The task is to identify various visual and auditory stimuli and to react to them by pressing the respective corresponding response buttons, using the response panel of the Vienna Test System. Median reaction time and correct responses were used to assess performance. Total duration of the test is 4&#x000a0;min.</p></sec><sec id="Sec15"><title>Useful field of view test</title><p id="Par24">The test of useful field of view (UFOV) is a computer-based test measuring detection time for three subtests (visual processing speed, divided attention, and selective attention) which involve attentional tasks of increasing difficulty (Edwards et al., <xref ref-type="bibr" rid="CR11">2005</xref>). Total detection time was computed by summing the threshold scores for the three subtests. Total duration of the test is approximately 7&#x000a0;min.</p></sec></sec><sec id="Sec16"><title>Statistical analyses</title><p id="Par25">Sample size calculation was based on detecting a minimally relevant difference with an effect size of 0.25 in SDLP, the primary measure of this study. Given a test-retest reliability of SDLP of at least <italic>r</italic>&#x02009;=&#x02009;0.70, a group of 22 participants should permit detection of a mean change of 2.0&#x000a0;cm, with a power of at least 90% and an <italic>&#x003b1;</italic> of .05. Using a Williams design to achieve balance in four treatment orders, a total of 24 participants were needed.</p><p id="Par26">SDLP in the highway driving test was analyzed using general linear model (GLM) for repeated measures with treatment (OXA10, OXA30, DIA10, PBO) as within-subject factor. Three paired sample <italic>t</italic> tests were conducted to assess the drug-placebo contrasts. Each parameter of the neurocognitive tests was analyzed using a <strike>2&#x02009;&#x000d7;&#x02009;4</strike> GLM repeated measures with treatment (OXA10, OXA30, DIA10, PBO) for sessions 1 and 2 separately. If a significant treatment effect was found, three paired sample <italic>t</italic> tests were conducted between each treatment and placebo. If the model assumptions were violated, a suitable transformation was selected for analysis; if the assumption remained violated, a nonparametric method (i.e., Friedman test for a main effect and Wilcoxon signed-rank test for simple effects) was selected.</p><p id="Par27">Change scores for each of the dependent variables were transformed to z-scores, which were calculated across the pooled changes in the active treatment conditions relative to placebo. This allows for easy comparison across each of the various performance tests (Dry, Burns, Nettelbeck, Farquharson, and White, <xref ref-type="bibr" rid="CR9">2012</xref>). In addition, to compare the magnitudes of the drug-placebo differences between tests and parameters, effect size (ES) statistics for repeated measure designs were calculated (i.e. t<sub>c</sub>[2(1-r)/n]<sup>1/2</sup>; Dunlap, Cortina, Vaslow, and Burke, <xref ref-type="bibr" rid="CR10">1996</xref>). Effect sizes between 0 and 0.19 are considered small, between 0.20 and0.69 are considered moderate, and 0.70 or higher are considered large (Lakens, <xref ref-type="bibr" rid="CR21">2013</xref>).</p><p id="Par28">Finally, Pearson&#x02019;s correlations were used to correlate change scores in session 1 and session 2 for each of the dependent variables with drug-placebo changes in SDLP. All statistical analyses were done by using the Statistical Package for the Social Sciences for Windows (version 21; SPSS Inc., Chicago, IL, USA).</p></sec></sec><sec id="Sec17"><title>Results</title><sec id="Sec18"><title>Missing data</title><p id="Par29">One male participant did not participate in the OXA10 condition, due to reasons unrelated to the study drug. After DIA10, one female participant discontinued testing 3&#x000a0;h after drug intake, due to nausea. Consequently, no data were collected for this participant for the ANT in session 1, the driving test, and all neurocognitive tests in session 2. Due to technical problems, no data of the balance test were available for one participant in the eyes open condition in session 2 after OXA10. The dataset of one male participant was removed from statistical analysis, because of non-compliance in the PBO condition. Extreme outliers, defined as values below the first or above the third quartile, were removed from the respective parameter. In the ANT, two outliers were identified, one in the orienting and one in the conflict effect. In the UFOV test, eight outliers were identified in seven participants. In the PBT, one outlier was identified in the eyes closed condition.</p></sec><sec id="Sec19"><title>Highway driving test</title><p id="Par30">Nineteen of 90 driving tests (21.1%) were prematurely terminated. These driving tests were either terminated by the driving instructor as he judged the participant to be too drowsy to continue safely (i.e., in nine cases; two times after OXA10, two after DIA10, and five after OXA30) of by the participants when they felt to be too drowsy to continue safely (i.e., in ten cases: two times after OXA10, three after DIA10, and five after OXA30). In all of these cases, mean SDLP scores were calculated from the data collected up to the termination of the test.</p><p id="Par31">Table <xref rid="Tab1" ref-type="table">1</xref> presents the mean (SE) of the mean SDLP scores. Analysis of variance showed a significant difference between treatments (F<sub>3,17</sub>&#x02009;=&#x02009;19.67, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). Figure <xref rid="Fig2" ref-type="fig">2</xref> shows the mean changes (i.e., &#x00394;SDLP) from PBO compared to OXA10, DIA10, and OXA30. The mean SDLP score presented in Table <xref rid="Tab1" ref-type="table">1</xref> include all participants (i.e., <italic>n</italic>&#x02009;=&#x02009;22, <italic>n</italic>&#x02009;=&#x02009;21, <italic>n</italic>&#x02009;=&#x02009;22, <italic>n</italic>&#x02009;=&#x02009;21, for PBO, OXA10, OXA30, and DIA10, respectively). Because of missing data for one participant in the OXA10 and DIA10 condition, respectively, mean SDLP changes of OXA10 and DIA10 in Table <xref rid="Tab2" ref-type="table">2</xref> are calculated based on <italic>n</italic>&#x02009;=&#x02009;21. Figure <xref rid="Fig2" ref-type="fig">2</xref> shows mean SDLP changes of +&#x02009;1.83, +&#x02009;3.03, and +&#x02009;7.57&#x000a0;cm for OXA10, DIA10, and OXA30, respectively, indicating &#x00394;SDLP comparable to a BAC of &#x0003c;&#x02009;0.5, 0.5&#x02013;0.8, and &#x0003e;&#x02009;0.8&#x000a0;g/L, respectively.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Mean (SE) of laboratory tests, overall effects of treatment, and paired sample <italic>t</italic> tests</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2"/><th colspan="4">Mean (SE)</th><th colspan="2">Overall effect</th><th colspan="3">Paired <italic>t</italic> tests</th></tr><tr><th>Test</th><th>Time of testing</th><th>OXA10 (<italic>n</italic>&#x02009;=&#x02009;21)</th><th>OXA30 (<italic>n</italic>&#x02009;=&#x02009;22)</th><th>DIA10 (<italic>n</italic>&#x02009;=&#x02009;21)</th><th>PBO (<italic>n</italic>&#x02009;=&#x02009;22)</th><th>
<italic>F</italic>
</th><th>
<italic>P</italic>
</th><th>OXA10-PBO</th><th>OXA30-PBO</th><th>DIA 10-PBO</th></tr></thead><tbody><tr><td colspan="11">Highway driving test</td></tr><tr><td>&#x02003;SDLP (cm)</td><td>+&#x02009;4&#x000a0;h</td><td>18.47 (0.90)</td><td>24.15 (1.36)</td><td>19.47 (0.89)</td><td>16.58 (0.65)</td><td>19.67</td><td>&#x0003c;&#x02009;0.001</td><td>&#x0003c;&#x02009;0.01</td><td>&#x0003c;&#x02009;0.001</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td colspan="11">Psychomotor vigilance test</td></tr><tr><td>Inverse reaction time</td><td>+&#x02009;2&#x000a0;h<break/>+&#x02009;6&#x000a0;h</td><td>4.07 (0.09)<break/>4.13 (0.09)</td><td>3.35 (0.14)<break/>3.85 (0.13)</td><td>3.86 (0.10)<break/>4.13 (0.10)</td><td>4.14 (0.09)<break/>4.13 (0.11)</td><td>13.40<break/>NS</td><td>&#x0003c;&#x02009;0.001</td><td>&#x02013;</td><td>&#x0003c;&#x02009;0.001</td><td>&#x0003c;&#x02009;.001</td></tr><tr><td>&#x02003;Lapses (#)*</td><td>+&#x02009;2&#x000a0;h<break/>+&#x02009;6&#x000a0;h</td><td>0.90 (1.38)<break/>1.19 (0.72)</td><td>11.86 (3.15)<break/>4.77 (1.79)</td><td>2.29 (0.74)<break/>0.90 (0.31)</td><td>0.64 (0.16)<break/>0.77 (0.29)</td><td>&#x003c7; <sup>2</sup>&#x02009;=&#x02009;38.87<break/>&#x003c7; <sup>2</sup>&#x02009;=&#x02009;10.29</td><td>&#x0003c;&#x02009;0.001<break/>&#x0003c;&#x02009;0.05</td><td>&#x02013;</td><td>&#x0003c;&#x02009;0.001<break/>&#x0003c;&#x02009;0.01</td><td>&#x0003c;&#x02009;0.05-</td></tr><tr><td>&#x02003;Mean reaction time (ms)</td><td>+&#x02009;2&#x000a0;h<break/>+&#x02009;6&#x000a0;h</td><td>258 (7)<break/>254 (6)</td><td>454 (68)<break/>311 (34)</td><td>277 (9)<break/>255 (7)</td><td>251 (5)<break/>255 (7)</td><td>4.61<break/>NS</td><td>&#x0003c;&#x02009;0.05</td><td>&#x02013;</td><td>&#x0003c;&#x02009;0.01</td><td>&#x0003c;&#x02009;0.01</td></tr><tr><td colspan="11">Critical tracking test</td></tr><tr><td>&#x02003;Critical lambda (rad/s)</td><td>+&#x02009;2&#x000a0;h<break/>+&#x02009;6&#x000a0;h</td><td>3.08 (0.12)<break/>3.01 (0.14)</td><td>2.49 (0.13)<break/>3.00 (0.13)</td><td>3.00 (0.09)<break/>3.26 (0.11)</td><td>3.34 (0.10)<break/>3.23 (0.11)</td><td>13.17<break/>NS</td><td>&#x0003c;&#x02009;0.001</td><td>&#x0003c;&#x02009;0.05<break/>-</td><td>&#x0003c;&#x02009;0.001<break/>-</td><td>&#x0003c;&#x02009;0.01<break/>-</td></tr><tr><td colspan="11">Divided attention test<sup>a</sup></td></tr><tr><td>&#x02003;Primary task: z-AE&#x02009;+&#x02009;z-lg10(CL)</td><td>+&#x02009;2&#x000a0;h<break/>+&#x02009;6&#x000a0;h</td><td>&#x02212;&#x02009;0.09 (0.46)<break/>&#x02212;&#x02009;0.53 (0.38)</td><td>1.97 (0.53)<break/>0.32 (0.45)</td><td>0.82 (0.36)<break/>&#x02212;&#x02009;0.18 (0.39)</td><td>&#x02212;&#x02009;0.69 (0.36)<break/>&#x02212;&#x02009;0.63 (0.38)</td><td>11.15<sup>a</sup><break/>NS<sup>a</sup></td><td>&#x0003c;&#x02009;0.01</td><td>&#x02013;</td><td>&#x0003c;&#x02009;0.001</td><td>&#x0003c;&#x02009;0.01</td></tr><tr><td>&#x02003;Secondary task: reaction time<break/>(ms)</td><td>+&#x02009;2&#x000a0;h<break/>+&#x02009;6&#x000a0;h</td><td>1966 (91)<break/>1892 (81)</td><td>2323 (91)<break/>2105 (70)</td><td>2152 (61)<break/>1975 (80)</td><td>1883 (65)<break/>1859 (74)</td><td>16.33<sup>a</sup><break/>NS<sup>a</sup></td><td>0.001</td><td>&#x02013;</td><td>&#x0003c;&#x02009;0.001</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td colspan="11">Attention network test</td></tr><tr><td>&#x02003;Mean total reaction time (ms)</td><td>+&#x02009;2&#x000a0;h<break/>+&#x02009;6&#x000a0;h</td><td>584 (21)<break/>558 (21)</td><td>730 (28)<break/>626 (26)</td><td>630 (26)<break/>594 (24)</td><td>547 (18)<break/>560 (22)</td><td>26.48<break/>6.67</td><td>&#x0003c;&#x02009;0.001<break/>&#x0003c;&#x02009;0.01</td><td>0.001<break/>-</td><td>&#x0003c;&#x02009;.001<break/>&#x0003c;&#x02009;0.001</td><td>&#x0003c;&#x02009;0.001<break/>&#x0003c;&#x02009;0.05</td></tr><tr><td>&#x02003;Conflict effect (ms)</td><td>+&#x02009;2&#x000a0;h<break/>+&#x02009;6&#x000a0;h</td><td>124 (10)<break/>120 (10)</td><td>148 (13)<break/>128 (8)</td><td>125 (7)<break/>127 (9)</td><td>105 (6)<break/>116 (7)</td><td>5.57<sup>b</sup><break/>NS</td><td>&#x0003c;&#x02009;0.01</td><td>&#x0003c;&#x02009;0.05</td><td>&#x0003c;&#x02009;0.01</td><td>&#x0003c;&#x02009;0.05</td></tr><tr><td>&#x02003;Orienting effect (ms)</td><td>+&#x02009;2&#x000a0;h<break/>+&#x02009;6&#x000a0;h</td><td>49 (5)<break/>54 (5)</td><td>68 (12)<break/>63 (6)</td><td>63 (5)<break/>51 (6)</td><td>47 (5)<break/>51 (5)</td><td>9.82<sup>b</sup><break/>NS</td><td>0.001</td><td/><td/><td>&#x0003c;&#x02009;0.01</td></tr><tr><td>&#x02003;Alerting effect (ms)</td><td>+&#x02009;2&#x000a0;h<break/>+&#x02009;6&#x000a0;h</td><td>53 (7)<break/>48 (6)</td><td>71 (8)<break/>64 (8)</td><td>58 (9)<break/>61 (7)</td><td>63 (6)<break/>52 (6)</td><td>NS<break/>NS</td><td/><td/><td/><td/></tr><tr><td colspan="11">Digit symbol substitution test</td></tr><tr><td>&#x02003;Correct responses (#)</td><td>+&#x02009;2&#x000a0;h<break/>+&#x02009;6&#x000a0;h</td><td>92.05 (2.97)<break/>99.33 (2.64)</td><td>73.41 (3.05)<break/>89.95 (2.26)</td><td>88.95 (2.83)<break/>96.48 (2.89)</td><td>97.59 (2.23)<break/>98.09 (2.89</td><td>22.71<break/>6.80</td><td>&#x0003c;&#x02009;0.001<break/>&#x0003c;&#x02009;0.01</td><td>&#x0003c;&#x02009;0.01<break/>-</td><td>&#x0003c;&#x02009;0.001<break/>0.001</td><td>&#x0003c;&#x02009;0.001<break/>-</td></tr><tr><td colspan="11">Useful field of view <sup>c</sup></td></tr><tr><td>&#x02003;Total detection time (ms)</td><td>+&#x02009;2&#x000a0;h<break/>+&#x02009;6&#x000a0;h</td><td>89 (7)<break/>86 (6)</td><td>161 (23)<break/>95 (6)</td><td>105 (10)<break/>92 (9)</td><td>107 (14)<break/>85 (7)</td><td>4.51<sup>c</sup><break/>NS<sup>c</sup></td><td>0.02</td><td>&#x02013;</td><td>0.02</td><td>&#x02013;</td></tr><tr><td colspan="11">Postural balance test</td></tr><tr><td>&#x02003;Eyes open&#x02013;ln area 95 (cm<sup>2</sup>)</td><td>+&#x02009;2&#x000a0;h<break/>+&#x02009;6&#x000a0;h</td><td>0.69 (0.09)<break/>0.38 (0.09)</td><td>1.48 (0.18)<break/>0.87 (0.14)</td><td>0.79 (0.15)<break/>0.90 (0.10)</td><td>0.26 (0.09)<break/>0.51 (0.10)</td><td>10.10<break/>5.88</td><td>&#x0003c;&#x02009;0.001<break/>&#x0003c;&#x02009;0.01</td><td>&#x0003c;&#x02009;0.01<break/>-</td><td>&#x0003c;&#x02009;0.001<break/>&#x0003c;&#x02009;0.05</td><td>0.01<break/>0.001</td></tr><tr><td>&#x02003;Eyes closed&#x02013;ln area 95 (cm<sup>2</sup>)</td><td>+&#x02009;2&#x000a0;h<break/>+&#x02009;6&#x000a0;h</td><td>1.01 (0.14)<break/>0.68 (0.10)</td><td>1.58 (0.19)<break/>1.25 (0.15)</td><td>1.02 (0.17)<break/>0.80 (0.13)</td><td>0.70 (0.10)<break/>0.71 (0.09)</td><td>6.56<sup>b</sup><break/>6.76</td><td>&#x0003c;&#x02009;0.01<break/>&#x0003c;&#x02009;0.01</td><td>-<break/>-</td><td>&#x0003c;&#x02009;0.001<break/>&#x0003c;&#x02009;0.001</td><td>&#x02013;</td></tr><tr><td colspan="11">Determination test</td></tr><tr><td>&#x02003;Median reaction time (ms)</td><td>+&#x02009;2&#x000a0;h<break/>+&#x02009;6&#x000a0;h</td><td>740 (20)<break/>706 (16)</td><td>810 (23)<break/>739 (17)</td><td>767 (19)<break/>707 (17)</td><td>714 (15)<break/>689 (15)</td><td>8.14<break/>NS</td><td>0.001</td><td>&#x0003c;&#x02009;0.05</td><td>&#x0003c;&#x02009;0.001</td><td>&#x0003c;&#x02009;0.05<break/>-</td></tr><tr><td>&#x02003;Correct responses (#)</td><td>+&#x02009;2&#x000a0;h<break/>+&#x02009;6&#x000a0;h</td><td>262 (9)<break/>279 (7)</td><td>230 (11)<break/>254 (10)</td><td>256 (8)<break/>281 (7)</td><td>273 (8)<break/>279 (9)</td><td>5.12<break/>NS</td><td>0.01</td><td>-<break/>-</td><td>0.001</td><td>-<break/>-</td></tr></tbody></table><table-wrap-foot><p><italic>SE</italic> standard error, <italic>OXA10</italic> oxazepam 10&#x000a0;mg, <italic>OXA30</italic> oxazepam 30&#x000a0;mg, <italic>DIA10</italic> diazepam 10&#x000a0;mg, <italic>PBO</italic> placebo, <italic>SDLP</italic> standard deviation of lateral position, <italic>z-AE</italic> z-score of average tracking error, <italic>z-log(CL)</italic> z-score of log transformed number of control losses, <italic>ln</italic> natural log</p><p>&#x0201c;*&#x0201d;because assumptions for general linear model were violated, a non-parametric Friedman test was conducted with Wilcoxon signed-rank tests to examine drug-placebo contrasts</p><p><sup>a</sup><italic>n</italic>&#x02009;=&#x02009;10</p><p><sup>b</sup><italic>n</italic>&#x02009;=&#x02009;19</p><p><sup>c</sup><italic>n</italic>&#x02009;=&#x02009;14</p></table-wrap-foot></table-wrap><fig id="Fig2"><label>Fig. 2</label><caption><p>Mean changes of standard deviation of lateral position (&#x00394;SDLP) after oxazepam 10&#x000a0;mg (OXA10), oxazepam 30&#x000a0;mg (OXA30), diazepam 10&#x000a0;mg (DIA10) relative to placebo (PBO). **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001. <italic>Error bars</italic> indicate the standard error of the mean. To indicate clinical relevance, cut-off values of SDLP changes at a blood alcohol concentration of 0.5, 0.8, and 1.0&#x000a0;g/L are added (Louwerens et al. <xref ref-type="bibr" rid="CR26">1987</xref>)</p></caption><graphic xlink:href="213_2018_4844_Fig2_HTML" id="MO2"/></fig><table-wrap id="Tab2"><label>Table 2</label><caption><p>Mean difference scores with 95% confidence intervals with performance after normal night of sleep, mean placebo-normalized absolute z-scores, effect sizes (Dunlap&#x02019;s) of neurocognitive tests of the mean differences of OXA10, OXA30, and DIA10g compared to placebo and correlations between mean changes of neurocognitive tests and changes in SDLP after OXA10, OXA30, and DIA10</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Test</th><th/><th colspan="2">OXA10 vs PLA</th><th colspan="2">OXA30 vs PLA</th><th colspan="2">DIA10 vs PLA</th><th>OXA10 vs PLA</th><th>OXA30 vs PLA</th><th>DIA10 vs PLA</th><th>OXA10<sup>a</sup></th><th>OXA30<sup>a</sup></th><th>DIA10<sup>a</sup></th></tr><tr><th>Time of testing</th><th>&#x00394;</th><th>[95% CI]</th><th>&#x00394;</th><th>[95% CI]</th><th>&#x00394;</th><th>[95% CI]</th><th colspan="3">Effect sizes</th><th colspan="3"><italic>r</italic> &#x00394;SDLP</th></tr></thead><tbody><tr><td colspan="14">Highway driving test</td></tr><tr><td>&#x02003;SDLP (cm)</td><td>+&#x02009;4&#x000a0;h</td><td>1.83</td><td>[0.59, 3.08]</td><td>7.68</td><td>[5.28, 10.08]</td><td>3.03</td><td>[1.96, 4.10]</td><td>0.47<sup>+</sup></td><td>1.39<sup>++</sup></td><td>0.77<sup>++</sup></td><td/><td/><td/></tr><tr><td colspan="14">Psychomotor vigilance test</td></tr><tr><td>&#x02003;Inverse reaction time</td><td>+&#x02009;2&#x000a0;h<break/>+&#x02009;6&#x000a0;h</td><td>&#x02212;&#x02009;0.07<break/>0.01</td><td>[&#x02212;&#x02009;0.26, 0.24]<break/>[&#x02212;&#x02009;0.13, 0.15]</td><td>&#x02212;&#x02009;0.79<break/>&#x02212;&#x02009;0.28</td><td>[&#x02212;&#x02009;1.03, &#x02212;&#x02009;0.55]<break/>[&#x02212;&#x02009;0.47, &#x02212;&#x02009;0.09]</td><td>&#x02212;&#x02009;0.29<break/>&#x02212;&#x02009;0.01</td><td>[&#x02212;&#x02009;0.42, &#x02212;&#x02009;0.15]<break/>[&#x02212;&#x02009;0.13, 0.12]</td><td>-<break/>-</td><td>1.38<sup>++</sup><break/>-</td><td>0.65<sup>+</sup><break/>-</td><td>-<break/>-</td><td>-<break/>&#x02212;&#x02009;0.56**</td><td>-<break/>-</td></tr><tr><td>&#x02003;Lapses</td><td>+&#x02009;2&#x000a0;h<break/>+ 6&#x000a0;h</td><td>0.29<break/>0.43</td><td>[&#x02212;&#x02009;0.45, 1.02]<break/>[&#x02212;&#x02009;0.79, 1.65]</td><td>11.23<break/>4.00</td><td>[4.74, 17.71]<break/>[0.23, 7.77]</td><td>1.59<break/>0.10</td><td>[0.05, 3.13]<break/>[&#x02212;&#x02009;0.58, 0.77]</td><td>-<break/>-</td><td>0.95<sup>++</sup><break/>0.67<sup>+</sup></td><td>0.69<sup>+</sup><break/>-</td><td>-<break/>-</td><td>-<break/>-</td><td>-<break/>-</td></tr><tr><td>&#x02003;Mean reaction time</td><td>+&#x02009;2&#x000a0;h<break/>+&#x02009;6&#x000a0;h</td><td>10<break/>1</td><td>[&#x02212;&#x02009;2, 21]<break/>[&#x02212;&#x02009;10.27, 12.39]</td><td>204<break/>56</td><td>[64, 343]<break/>[&#x02212;&#x02009;9, 121]</td><td>26<break/>0</td><td>[11, 42]<break/>[&#x02212;&#x02009;10, 10]</td><td>-<break/>-</td><td>0.78<sup>++</sup><break/>0.39<sup>+</sup></td><td>0.69<sup>+</sup><break/>0.00</td><td>-<break/>-</td><td>-<break/>-</td><td>-<break/>-</td></tr><tr><td colspan="14">Critical tracking test</td></tr><tr><td>&#x02003;Critical lambda</td><td>+&#x02009;2&#x000a0;h<break/>+&#x02009;6&#x000a0;h</td><td>&#x02212;&#x02009;0.26<break/>&#x02212;&#x02009;0.23</td><td>[&#x02212;&#x02009;0.50, &#x02212;&#x02009;0.02]<break/>[&#x02212;&#x02009;0.50, 0.04]</td><td>&#x02212;&#x02009;0.85<break/>&#x02212;&#x02009;0.23</td><td>[&#x02212;&#x02009;1.12, &#x02212;&#x02009;0.58]<break/>[&#x02212;&#x02009;0.48, 0.03]</td><td>&#x02212;&#x02009;0.34<break/>0.03</td><td>[&#x02212;&#x02009;0.56, &#x02212;&#x02009;0.12]<break/>[&#x02212;&#x02009;0.15, 0.22]</td><td>0.50<sup>+</sup><break/>-</td><td>1.57<sup>++</sup><break/>-</td><td>0.77<sup>++</sup><break/>-</td><td>-<break/>-</td><td>-<break/>-</td><td>-<break/>-</td></tr><tr><td colspan="14">Divided attenion test</td></tr><tr><td>&#x02003;Primary task: z-AE&#x02009;+&#x02009;z-lg10(CL)</td><td>+&#x02009;2&#x000a0;h<break/>+&#x02009;6&#x000a0;h</td><td>0.57<break/>0.02</td><td>[&#x02212;&#x02009;0.36, 1.50]<break/>[&#x02212;&#x02009;0.70, 0.73]</td><td>2.90<break/>1.10</td><td>[1.77, 4.02]<break/>[0.22, 1.99]</td><td>1.37<break/>0.47</td><td>[0.54, 2.19]<break/>[&#x02212;&#x02009;0.20, 1.13]</td><td>-<break/>-</td><td>1.71<sup>++</sup><break/>-</td><td>0.90<sup>++</sup><break/>-</td><td>-<break/>-</td><td>-<break/>-</td><td>-<break/>-</td></tr><tr><td>&#x02003;Secondary task: reaction time</td><td>+&#x02009;2&#x000a0;h<break/>+&#x02009;6&#x000a0;h</td><td>117<break/>39</td><td>[&#x02212;&#x02009;123, 356]<break/>[&#x02212;&#x02009;114, 191]</td><td>567<break/>138</td><td>[367, 768]<break/>[&#x02212;&#x02009;188, 464]</td><td>331<break/>80</td><td>[169, 493]<break/>[&#x02212;&#x02009;62, 222]</td><td>-<break/>-</td><td>1.66<sup>+</sup><break/>&#x02212;<sup>+</sup></td><td>1.16<sup>++</sup><break/>-</td><td>-<break/>-</td><td>-<break/>-</td><td>-<break/>-</td></tr><tr><td colspan="14">Attention network test</td></tr><tr><td>&#x02003;Mean total reaction time</td><td>+&#x02009;2&#x000a0;h<break/>+&#x02009;6&#x000a0;h</td><td>45<break/>11</td><td>[20, 70]<break/>[&#x02212;&#x02009;8, 30]</td><td>183<break/>67</td><td>[142, 224]<break/>[38, 95]</td><td>82<break/>35</td><td>[47, 117]<break/>[5, 64]</td><td>0.49<sup>+</sup><break/>-</td><td>1.51<sup>++</sup><break/>0.56<sup>+</sup></td><td>0.75<sup>++</sup><break/>0.31<sup>+</sup></td><td>-<break/>0.58**</td><td>-<break/>-</td><td>-<break/>0.55**</td></tr><tr><td>&#x02003;Conflict effect</td><td>+&#x02009;2&#x000a0;h<break/>+&#x02009;6&#x000a0;h</td><td>19<break/>5</td><td>[3, 35]<break/>[&#x02212;&#x02009;11, 22]</td><td>45<break/>12</td><td>[17, 73]<break/>[&#x02212;&#x02009;3, 27]</td><td>21<break/>11</td><td>[5, 37]<break/>[&#x02212;&#x02009;6, 28]</td><td>0.44<sup>+</sup><break/>-</td><td>0.93<sup>++</sup><break/>-</td><td>0.69<sup>+</sup><break/>-</td><td>-<break/>-</td><td>-<break/>-</td><td>-<break/>-</td></tr><tr><td>&#x02003;Orienting effect</td><td>+&#x02009;2&#x000a0;h<break/>+&#x02009;6&#x000a0;h</td><td>6<break/>5</td><td>[&#x02212;&#x02009;8, 20]<break/>[&#x02212;&#x02009;8, 18]</td><td>23<break/>12</td><td>[&#x02212;&#x02009;5, 51]<break/>[&#x02212;&#x02009;5, 30]</td><td>18<break/>&#x02212;&#x02009;1</td><td>[6, 31]<break/>[&#x02212;&#x02009;20, 17]</td><td>-<break/>-</td><td>-<break/>-</td><td>0.73<sup>++</sup><break/>-</td><td>-<break/>-</td><td>-<break/>-</td><td>-<break/>-</td></tr><tr><td>&#x02003;Alerting effect</td><td>+&#x02009;2&#x000a0;h<break/>+&#x02009;6&#x000a0;h</td><td>&#x02212;&#x02009;10<break/>&#x02212;&#x02009;1</td><td>[&#x02212;&#x02009;27, 8]<break/>[&#x02212;&#x02009;14, 12]</td><td>7<break/>12</td><td>[&#x02212;&#x02009;10, 24]<break/>[&#x02212;&#x02009;7, 31]</td><td>&#x02212;&#x02009;6<break/>11</td><td>[&#x02212;&#x02009;31, 20]<break/>[&#x02212;&#x02009;6, 29]</td><td>-<break/>-</td><td>-<break/>-</td><td>-<break/>-</td><td>-<break/>-</td><td>-<break/>-</td><td>-<break/>-</td></tr><tr><td colspan="14">Digit symbol substitution test</td></tr><tr><td>&#x02003;Correct responses</td><td>+&#x02009;2&#x000a0;h<break/>+&#x02009;6&#x000a0;h</td><td>&#x02212;&#x02009;6.33<break/>&#x02212;&#x02009;0.05</td><td>[&#x02212;&#x02009;10.37, &#x02212;&#x02009;2.29]<break/>[&#x02212;&#x02009;3.31, 3.21]</td><td>&#x02212;&#x02009;24.18<break/>&#x02212;&#x02009;8.14</td><td>[&#x02212;&#x02009;29.81, &#x02212;&#x02009;18.56]<break/>[&#x02212;&#x02009;12.52, &#x02212;&#x02009;3.76]</td><td>&#x02212;&#x02009;8.64<break/>&#x02212;&#x02009;1.67</td><td>[&#x02212;&#x02009;12.84, &#x02212;&#x02009;4.43]<break/>[&#x02212;&#x02009;6.20, 2.86]</td><td>0.50<sup>+</sup><break/>-</td><td>1.89<sup>++</sup><break/>0.65<sup>+</sup></td><td>0.70<sup>++</sup><break/>-</td><td>-<break/>-</td><td>-<break/>-</td><td>-<break/>-</td></tr><tr><td colspan="14">Useful field of view</td></tr><tr><td>&#x02003;Total detection time</td><td>+&#x02009;2&#x000a0;h<break/>+&#x02009;6&#x000a0;h</td><td>&#x02212;&#x02009;17<break/>1</td><td>[&#x02212;&#x02009;40, 7]<break/>[&#x02212;&#x02009;10, 12]</td><td>59<break/>9</td><td>[10, 109]<break/>[&#x02212;&#x02009;5, 23]</td><td>2<break/>4</td><td>[&#x02212;&#x02009;25, 29]<break/>[&#x02212;&#x02009;16, 24]</td><td>-<break/>-</td><td>0.69<sup>+</sup><break/>-</td><td>-<break/>-</td><td>-<break/>-</td><td>-<break/>-</td><td>-<break/>-</td></tr><tr><td colspan="14">Postural balance test</td></tr><tr><td>&#x02003;Eyes open&#x02013;ln area 95 (cm<sup>2</sup>)</td><td>+&#x02009;2&#x000a0;h<break/>+&#x02009;6&#x000a0;h</td><td>0.40<break/>&#x02212;&#x02009;0.14</td><td>[0.14, 0.67]<break/>[&#x02212;&#x02009;0.39, 0.11]</td><td>1.19<break/>0.38</td><td>[0.77, 1.61]<break/>[0.07, 0.70]</td><td>0.47<break/>0.31</td><td>[0.10, 0.83]<break/>[0.09, 0.54]</td><td>1.06<sup>++</sup></td><td>1.90<sup>++</sup><break/>0.66<sup>+</sup></td><td>0.95<sup>++</sup><break/>0.79<sup>++</sup></td><td>0.60**<break/>-</td><td>-<break/>-</td><td>-<break/>-</td></tr><tr><td>&#x02003;Eyes closed&#x02013;ln area 95 (cm<sup>2</sup>)</td><td>+&#x02009;2&#x000a0;h<break/>+&#x02009;6&#x000a0;h</td><td>0.28<break/>&#x02212;&#x02009;0.07</td><td>[&#x02212;&#x02009;0.04, 0.61]<break/>[&#x02212;&#x02009;0.25, 0.12]</td><td>0.87<break/>0.56]</td><td>[0.45, 1.28]<break/>[0.31, 0.82]</td><td>0.29<break/>0.03</td><td>[&#x02212;&#x02009;0.11, 0.69]<break/>[&#x02212;&#x02009;0.21, 0.27]</td><td>+<break/>-</td><td>1.26<sup>++</sup><break/>0.93<sup>++</sup></td><td>-<break/>-</td><td>-<break/>-</td><td>-<break/>-</td><td>-<break/>-</td></tr><tr><td colspan="14">Determination test</td></tr><tr><td>&#x02003;Median reaction time</td><td>+&#x02009;2&#x000a0;h<break/>+&#x02009;6&#x000a0;h</td><td>30<break/>18</td><td>[5, 55]<break/>[&#x02212;&#x02009;1, 37]</td><td>97<break/>46</td><td>[58, 136]<break/>[18, 74]</td><td>54<break/>14</td><td>[11,96]<break/>[&#x02212;&#x02009;10, 38]</td><td>0.34<sup>+</sup><break/>-</td><td>1.02<sup>++</sup><break/>-</td><td>0.67<sup>+</sup><break/>-</td><td>-<break/>-</td><td>-<break/>-</td><td>-<break/>-</td></tr><tr><td>&#x02003;Correct responses</td><td>+&#x02009;2&#x000a0;h<break/>+&#x02009;6&#x000a0;h</td><td>&#x02212;&#x02009;11<break/>&#x02212;&#x02009;2</td><td>[&#x02212;&#x02009;31, 9]<break/>[&#x02212;&#x02009;16, 13]</td><td>&#x02212;&#x02009;43<break/>&#x02212;&#x02009;25</td><td>[&#x02212;&#x02009;66, &#x02212;&#x02009;20]<break/>[&#x02212;&#x02009;45, 4]</td><td>&#x02212;&#x02009;17<break/>&#x02212;&#x02009;3</td><td>[&#x02212;&#x02009;36, 2]<break/>[&#x02212;&#x02009;14, 8]</td><td>-<break/>-</td><td>0.97<sup>++</sup><break/>-</td><td>-<break/>-</td><td>-<break/>-</td><td>-<break/>-</td><td>-<break/>-</td></tr></tbody></table><table-wrap-foot><p><italic>CI</italic> confidence interval, <italic>r</italic> correlation, <italic>SDLP</italic> standard deviation of lateral position, <italic>OXA10</italic> oxazepam 10&#x000a0;mg, <italic>OXA30</italic> oxazepam 30&#x000a0;mg, <italic>DIA10</italic> diazepam 10&#x000a0;mg, <italic>z-AE</italic> z-score of average tracking error, <italic>z-log(CL)</italic> z-score of log transformed number of control losses, <italic>ln</italic> natural log</p><p><sup>a</sup><italic>n</italic>&#x02009;=&#x02009;20</p><p><sup>+</sup>moderate effect size, <sup>++</sup>large effect size. **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec20"><title>Neurocognitive tests</title><p id="Par32">Table <xref rid="Tab1" ref-type="table">1</xref> presents a summary of the means and standard errors of the means (SE) of all performance scores and the results of the statistical analyses. In the PBT, A95 scores were not normally distributed and therefore log transformed (e.g., Boyle et al., <xref ref-type="bibr" rid="CR6">2009</xref>). After the log transformation, A95 scores were normally distributed. In the PVT, lapses were not normally distributed and therefore analyzed using non-parametric tests (i.e., Friedman test and Wilcoxon signed rank tests).</p><p id="Par33">The DAT was terminated 23 times (12.7%), as participants were unable to complete the test because of motor problems (&#x0003e;&#x02009;50 control losses): four (OXA10), ten (OXA30), four (DIA10) times in session 1; three times (OXA30) and once (DIA10) in session 2. In addition, the test was once terminated in session 1 after PBO. Secondary control measures were first analyzed. A Friedman test was conducted, as control losses were not normally distributed. A Friedman test showed a statistically significant difference in control losses depending on treatment, &#x003c7;<sup>2</sup> (7)&#x02009;=&#x02009;25.03, <italic>p</italic>&#x02009;=&#x02009;0.001. A combined score of control losses and tracking error was used to assess performance in the DAT. The distribution of control losses was highly skewed and transformations were applied to its logarithmic scores (log 10) before transformation to z-scores. Log 10 was applied to deal with zero values by using the formula NEWX&#x02009;=&#x02009;LG10 (X&#x02009;+&#x02009;1.</p><p id="Par34">Repeated measures analyses of variance showed a main effect of treatment in every parameter of the neurocognitive tests, except for orienting and alerting in the ANT. In session 1, all parameters showed impairment after OXA30 and DIA10 compared to PBO, except for the UFOV after DIA10. In session 1 after OXA10, significant impairment was found in all tests, except the PVT, DAT, and UFOV.</p><p id="Par35">In session 2 after OXA30, performance was still impaired in all tests except the CTT and UFOV; after DIA10, only the ANT and PBT with eyes open showed impairment. In session 2 after OXA10, no significant effect in any test was found.</p></sec><sec id="Sec21"><title>Effect sizes and correlations</title><p id="Par36">Table <xref rid="Tab2" ref-type="table">2</xref> shows a summary of mean treatment differences relative to PBO with 95% confidence intervals, Dunlap&#x02019;s effect sizes, and significant correlations between changes of performance in the neurocognitive tests and &#x00394;SDLP in the highway driving test.</p><p id="Par37">The ES of &#x00394;SDLP in the highway driving test were moderate after OXA10 (0.47) to large after DIA10 and OXA30 (0.77 and 1.39, respectively). In the neurocognitive tests, ES were generally moderate after OXA10, large after DIA10, and largest after OXA30. In addition, ES were larger in session 1 compared to session 2. Figure <xref rid="Fig3" ref-type="fig">3</xref> shows transformed z-scores of change scores for each of the significant dependent variables across the pooled changes in the active treatment conditions relative to placebo. For the PVT and the DT, only the parameters with highest transformed z-scores were reported.<fig id="Fig3"><label>Fig. 3</label><caption><p>Mean baseline-normalized significant z-scores of oxazepam 10&#x000a0;mg (OXA10), diazepam 10&#x000a0;mg (DIA10), and oxazepam 30&#x000a0;mg (OXA30) compared with placebo across dependent variables of neurocognitive tests. SDLP in the highway driving tests is included as reference test. PVT&#x02009;=&#x02009;psychomotor vigilance test, CTT&#x02009;=&#x02009;critical tracking test, DAT&#x02009;=&#x02009;divided attention test, ANT&#x02009;=&#x02009;attention network test, DSST&#x02009;=&#x02009;digit symbol substitution test, UFOV&#x02009;=&#x02009;useful field of view, PBT&#x02009;=&#x02009;postural balance test, DT&#x02009;=&#x02009;determination test, RT&#x02009;=&#x02009;reaction time, TE&#x02009;=&#x02009;tracking error, CL&#x02009;=&#x02009;control losses, A95 EO&#x02009;=&#x02009;area 95% eyes open. <italic>Error bars</italic> indicate the standard error of the mean</p></caption><graphic xlink:href="213_2018_4844_Fig3_HTML" id="MO3"/></fig></p><p id="Par38">Table <xref rid="Tab2" ref-type="table">2</xref> depicts correlations between neurocognitive test performance changes and &#x00394;SDLP. These correlations show that significance (i.e., <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01) was only found between performance changes in PVT after OXA30 in session 2, in ANT after OXA10 and DIA10 in session 2, and PBT after OXA10 in session 1.</p></sec></sec><sec id="Sec22"><title>Discussion</title><p id="Par39">The main aim of the current study was to validate the sensitivity of a range of neurocognitive tests to the effects of OXA10, OXA30, and DIA10 and to compare these effects with driving impairment (i.e., changes in SDLP) during the highway driving test. An increase of SDLP in the highway driving test was found after all three benzodiazepine treatments compared to PBO. After OXA10, a significant SDLP increase of 1.83&#x000a0;cm was found, corresponding to minor impairment as found at a blood alcohol concentration (BAC) of &#x0003c;&#x02009;0.5&#x000a0;g/L; after DIA10, SDLP increased with 3.03&#x000a0;cm, corresponding to moderate impairment as found at a BAC between 0.5&#x02013;0.8&#x000a0;g/L; and after OXA30, SDLP increased with 7.57&#x000a0;cm, corresponding to severe impairment as found at a BAC of &#x0003e;&#x02009;1.0&#x000a0;g/L (Louwerens et al. <xref ref-type="bibr" rid="CR26">1987</xref>). In general, neurocognitive test performance 2&#x000a0;h after intake showed comparable impairment as found on SDLP in the highway driving test, while the drug effects were diminished 6&#x000a0;h after intake. At that time, impairment after OXA30 was still significant, but was nearly absent after intake of OXA10 and DIA10.</p><p id="Par40">Based on the mean changes and the magnitude of the effect sizes, several tests (i.e., the ANT, DSST, PBT, and DT) showed to be sensitive to detect mild drug effects after OXA10, which was comparable to changes in SDLP in the highway driving test. These tests are potential candidates to be included in early phase clinical trials to test mild drug effects. As initial tools, neurocognitive tests showing higher levels of impairment are preferable above neurocognitive tests showing lower levels of drug-induced impairment, as generally these tests indicating lower levels of impairment might underestimate the mean drug effect. However, it should be noted that the DSST and ANT were only sensitive to effects of alcohol while BAC was 0.8&#x000a0;g/L, but not at lower doses (Jongen et al., <xref ref-type="bibr" rid="CR17">2014</xref>). This indicates that the ANT and DSST seem to be more sensitive to the effect of benzodiazepines as compared to alcohol.</p><p id="Par41">Surprisingly, the DAT and PVT were unable to detect impairment induced by OXA10 and showed lower magnitude of impairment compared to SDLP in the highway driving test. This was rather unexpected as previous studies showed that these tests were sensitive to impairment of low and moderate doses of alcohol (Jongen et al. <xref ref-type="bibr" rid="CR17">2014</xref>) and sleep deprivation (Jongen et al., <xref ref-type="bibr" rid="CR18">2015</xref>). In addition, the DAT has previously shown to be sensitive to the effects of various medicinal drugs, such as of anxiolytics (Leufkens, Vermeeren, Smink, van Ruitenbeek, and Ramaekers, <xref ref-type="bibr" rid="CR23">2007</xref>), hypnotics (Leufkens, Ramaekers, de Weerd, Riedel, and Vermeeren, <xref ref-type="bibr" rid="CR22">2014</xref>; Leufkens, Lund, and Vermeeren, <xref ref-type="bibr" rid="CR24">2009</xref>; Vermeeren et al., <xref ref-type="bibr" rid="CR47">2002</xref>), antihistamines (Vuurman et al., <xref ref-type="bibr" rid="CR50">2004</xref>), and antidepressants (Robbe and O&#x02019;Hanlon, <xref ref-type="bibr" rid="CR39">1995</xref>). The failure of the DAT to show significant impairment after OXA10 in the present study might be explained by the large number of missing data, due to termination of four tests. As a result, the dataset might have been underpowered.</p><p id="Par42">In contrast to the DAT, only one previous study used the PVT to assess drug effect on performance (Leufkens et al. <xref ref-type="bibr" rid="CR25">2014</xref>). Leufkens et al. (<xref ref-type="bibr" rid="CR25">2014</xref>) used the PVT and the on-the-road highway driving test to compare the residual effects of zopiclone 7.5&#x000a0;mg and placebo. Results showed that performance in the on-the-road highway driving test was significantly impaired after zopiclone 7.5&#x000a0;mg, but performance in the PVT did not differ from placebo. Together with the results of the present study, this suggests that the PVT and DAT can be a useful tool for initial screening of a moderate to severe drug effect in early phase clinical trials, as these tests are able to detect moderate to large drug effect on sustained and divided attention. However, the PVT lacks sensitivity to mild drug effects, indicating that the use of the PVT in clinical trials might lead to failing to detect mild impairing drug effects on sustained attention. Later phase clinical studies assessing mean drug effects on driving performance should therefore include sensitive measures of on-the-road driving performance (e.g., SDLP) to provide the final evidence of the impairing potential of a drug on driving ability.</p><p id="Par43">The levels of drug-induced impairment found in these neurocognitive tests after intake of these prototypical sedative drugs can be used as thresholds of drug-induced impairment in future studies. A recent review indicated the lack of information regarding clinical relevance of neurocognitive impairment in medicated patient populations (van der Sluiszen et al., <xref ref-type="bibr" rid="CR43">2017</xref>). The present results can help to identify those patient groups who are at risk in traffic by, for example, comparing the benchmarks in neurocognitive tests after acute drug administration with long-term use of drugs in patient populations.</p><p id="Par44">The present study found that only 4 out of 96 correlations between driving impairment and neurocognitive test performance were statistically significant. These correlations were a best moderately strong, and found in 3 out of 8 neurocognitive tests, i.e., the PVT, ANT, and PBT. No parameter consistently correlated (i.e., for all three treatment conditions) with driving impairment. In addition, no significant correlations were found between performance changes in the DAT, CTT, DSST, DT, and UFOV, showing that these tests are not associated with driving impairment as measured with changes in SDLP. The results of the present study are in line with previous reviews concluding that only some neurocogntive correlate moderately at best with actual driving impairment (Jongen et al. <xref ref-type="bibr" rid="CR18">2015</xref>; Ramaekers, <xref ref-type="bibr" rid="CR37">2003</xref>; Verster and Roth, <xref ref-type="bibr" rid="CR49">2012</xref>). Overall, neurocognitive tests clearly measure different aspects of drug-induced impairment as compared to SDLP. However, neurocognitive tests may have added value in assessing these drug effects in early phase clinical trials as these are easy to administer and cost-effective.</p><p id="Par45">A limitation of the present study may be that neurocognitive tasks are compared with SDLP to assess drug-induced driving impairment. Although SDLP reflects road tracking control as a fundamental and realistic aspect of driving, it only measures highly automated performance at an operational level as part of driving performance (Michon, <xref ref-type="bibr" rid="CR28">1989</xref>). Driving performance also includes risk assessment, decision making and interaction with other road users. The predictive validity of the selected neurocognitive tests to measure drug-induced driving impairment could be underestimated as these tests might measure different relevant aspects of driving performance. Nevertheless, SDLP remains the most valid and sensitive measure to assess a drug&#x02019;s impairing potential on driving performance.</p><p id="Par46">In conclusion, it was shown that single doses of OXA10 caused minor, DIA10 moderate, and OXA30 severe driving impairment. The DSST, ANT, PBT, and DT were able to detect mild effects of OXA10, but&#x02014;except for the ANT&#x02014;were not associated with driving impairment. These tests are potential candidate tests to measure mild drug effects in early phase clinical trials. However, no neurocognitive test is able to replace the on-the-road highway driving test.</p></sec></body><back><ack><p>The authors would like to thank Anita van Oers, Eline Haijen, Ellen Houben, Shamyra Coleman, Jorn Jongen, and Caroline Steins for their assistance in data collection, Cees van Leeuwen MD, for the medical supervision, Henk Brauers and Hans Sleebe for ensuring the safety of the participants during the highway driving test, and Irma Brauers for the logistic work.</p></ack><notes notes-type="COI-statement"><title>Compliance with ethical standards</title><p>The study was conducted in accordance with the code of ethics on human experimentation established by the declaration of Helsinki (1964) and amended in Seoul (2008). All participants were informed about the study&#x02019;s goal, procedures, and potential hazards in writing, and they gave their informed consent in writing. The Medical Ethics Committees of Maastricht University approved the study. Participants received a financial compensation for their participation in the study.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvarez</surname><given-names>F</given-names></name><name><surname>del R&#x000ed;o</surname><given-names>M</given-names></name></person-group><article-title>Medicinal drugs and driving: from research to clinical practice</article-title><source>Trends Pharmacol Sci</source><year>2002</year><volume>23</volume><issue>9</issue><fpage>441</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1016/S0165-6147(02)02083-7</pub-id><pub-id pub-id-type="pmid">12237157</pub-id></element-citation></ref><ref id="CR2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basner</surname><given-names>M</given-names></name><name><surname>Dinges</surname><given-names>DF</given-names></name></person-group><article-title>Maximizing sensitivity of the psychomotor vigilance test (PVT) to sleep loss</article-title><source>Sleep</source><year>2011</year><volume>34</volume><issue>5</issue><fpage>581</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1093/sleep/34.5.581</pub-id><pub-id pub-id-type="pmid">21532951</pub-id></element-citation></ref><ref id="CR3"><mixed-citation publication-type="other">Berghaus, G., &#x00026; Friedel, B. (1999). Guidelines on experimental studies undertaken to determine a medicinal drug&#x02019;s effect on driving or skills related to driving. Report of ICADTS Working Group</mixed-citation></ref><ref id="CR4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bezemer</surname><given-names>KD</given-names></name><name><surname>Smink</surname><given-names>BE</given-names></name><name><surname>van Maanen</surname><given-names>R</given-names></name><name><surname>Verschraagen</surname><given-names>M</given-names></name><name><surname>de Gier</surname><given-names>JJ</given-names></name></person-group><article-title>Prevalence of medicinal drugs in suspected impaired drivers and a comparison with the use in the general Dutch population</article-title><source>Forensic Sci Int</source><year>2014</year><volume>241</volume><fpage>203</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1016/j.forsciint.2014.06.004</pub-id><pub-id pub-id-type="pmid">24973726</pub-id></element-citation></ref><ref id="CR5"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Borkenstein</surname><given-names>R</given-names></name><name><surname>Crowther</surname><given-names>RF</given-names></name><name><surname>Shumate</surname><given-names>RP</given-names></name><name><surname>Zeil</surname><given-names>WW</given-names></name><name><surname>Zylinan</surname><given-names>R</given-names></name></person-group><source>The role of the drinking in traffic accidents</source><year>1964</year><publisher-loc>Bloomington, IN</publisher-loc><publisher-name>Department of Police Administration, Indiana University</publisher-name></element-citation></ref><ref id="CR6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyle</surname><given-names>J</given-names></name><name><surname>Danjou</surname><given-names>P</given-names></name><name><surname>Alexander</surname><given-names>R</given-names></name><name><surname>Calder</surname><given-names>N</given-names></name><name><surname>Gargano</surname><given-names>C</given-names></name><name><surname>Agrawal</surname><given-names>N</given-names></name><name><surname>Murphy</surname></name><name><surname>G</surname><given-names>M</given-names></name></person-group><article-title>Tolerability, pharmacokinetics and night-time effects on postural sway and critical flicker fusion of gaboxadol and zolpidem in elderly subjects</article-title><source>Br J Clin Pharmacol</source><year>2009</year><volume>67</volume><issue>2</issue><fpage>180</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2008.03331.x</pub-id><pub-id pub-id-type="pmid">19094161</pub-id></element-citation></ref><ref id="CR7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dassanayake</surname><given-names>T</given-names></name><name><surname>Michie</surname><given-names>P</given-names></name><name><surname>Carter</surname><given-names>G</given-names></name><name><surname>Jones</surname><given-names>A</given-names></name></person-group><article-title>Effects of benzodiazepines, antidepressants and opioids on driving: a systematic review and meta-analysis of epidemiological and experimental evidence</article-title><source>Drug Saf</source><year>2011</year><volume>34</volume><issue>2</issue><fpage>125</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.2165/11539050-000000000-00000</pub-id><pub-id pub-id-type="pmid">21247221</pub-id></element-citation></ref><ref id="CR8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinges</surname><given-names>DF</given-names></name><name><surname>Powell</surname><given-names>JW</given-names></name></person-group><article-title>Microcomputer analyses of performance on a portable, simple visual RT task during sustained operations</article-title><source>Behav Res Methods Instrum Comput</source><year>1985</year><volume>17</volume><issue>6</issue><fpage>652</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.3758/BF03200977</pub-id></element-citation></ref><ref id="CR9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dry</surname><given-names>MJ</given-names></name><name><surname>Burns</surname><given-names>NR</given-names></name><name><surname>Nettelbeck</surname><given-names>T</given-names></name><name><surname>Farquharson</surname><given-names>AL</given-names></name><name><surname>White</surname><given-names>JM</given-names></name></person-group><article-title>Dose-related effects of alcohol on cognitive functioning</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><issue>11</issue><fpage>e50977</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0050977</pub-id><pub-id pub-id-type="pmid">23209840</pub-id></element-citation></ref><ref id="CR10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunlap</surname><given-names>WP</given-names></name><name><surname>Cortina</surname><given-names>JM</given-names></name><name><surname>Vaslow</surname><given-names>JB</given-names></name><name><surname>Burke</surname><given-names>MJ</given-names></name></person-group><article-title>Meta-analysis of experiments with matched groups or repeated measures designs</article-title><source>Psychol Methods</source><year>1996</year><volume>1</volume><issue>2</issue><fpage>170</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1037/1082-989X.1.2.170</pub-id></element-citation></ref><ref id="CR11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>JD</given-names></name><name><surname>Vance</surname><given-names>DE</given-names></name><name><surname>Wadley</surname><given-names>VG</given-names></name><name><surname>Cissell</surname><given-names>GM</given-names></name><name><surname>Roenker</surname><given-names>DL</given-names></name><name><surname>Ball</surname><given-names>KK</given-names></name></person-group><article-title>Reliability and validity of useful field of view test scores as administered by personal computer</article-title><source>J Clin Exp Neuropsychol</source><year>2005</year><volume>27</volume><issue>5</issue><fpage>529</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1080/13803390490515432</pub-id><pub-id pub-id-type="pmid">16019630</pub-id></element-citation></ref><ref id="CR12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>McCandliss</surname><given-names>BD</given-names></name><name><surname>Sommer</surname><given-names>T</given-names></name><name><surname>Raz</surname><given-names>A</given-names></name><name><surname>Posner</surname><given-names>MI</given-names></name></person-group><article-title>Testing the efficiency and independence of attentional networks</article-title><source>J Cogn Neurosci</source><year>2002</year><volume>14</volume><issue>3</issue><fpage>340</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1162/089892902317361886</pub-id><pub-id pub-id-type="pmid">11970796</pub-id></element-citation></ref><ref id="CR13"><mixed-citation publication-type="other">FDA Guidance for Industry: <italic>Evaluating Drug Effects on the Ability to Operate a Motor Vehicle Guidance forIndustry</italic> (Draft Guidance) (January 2015), <bold>available at:</bold><ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM430374">http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM430374</ext-link></mixed-citation></ref><ref id="CR14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horne</surname><given-names>JA</given-names></name><name><surname>Ostberg</surname><given-names>O</given-names></name></person-group><article-title>A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms</article-title><source>Int J Chronobiol</source><year>1976</year><volume>4</volume><issue>2</issue><fpage>97</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">1027738</pub-id></element-citation></ref><ref id="CR15"><element-citation publication-type="book"><person-group person-group-type="author"><collab>International Council on Alcohol Drugs and Traffic Safety (ICADTS)</collab></person-group><source>Guidelines on studies undertaken to determine a medicinal drug&#x02019;s effect on driving or skills related to driving</source><year>1999</year><publisher-loc>Cologne</publisher-loc><publisher-name>Bundes Anstalt fuer Strassenwesen (BASt)</publisher-name><fpage>1</fpage><lpage>13</lpage></element-citation></ref><ref id="CR16"><mixed-citation publication-type="other">Jex, H. R., McDonnell, J. D., &#x00026; Phatak, A. V. (1966). A &#x0201c;critical&#x0201d; tracking task for man-machine research related to the operator&#x02019;s effective delay time. I. Theory and experiments with a first-order divergent controlled element. NASA CR-616. NASA Contractor Report. NASA CR. United States. National Aeronautics and Space Administration, 1&#x02013;105</mixed-citation></ref><ref id="CR17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jongen</surname><given-names>S</given-names></name><name><surname>Vuurman</surname><given-names>E</given-names></name><name><surname>Ramaekers</surname><given-names>J</given-names></name><name><surname>Vermeeren</surname><given-names>A</given-names></name></person-group><article-title>Alcohol calibration of tests measuring skills related to car driving</article-title><source>Psychopharmacology</source><year>2014</year><volume>231</volume><issue>12</issue><fpage>2435</fpage><lpage>2447</lpage><pub-id pub-id-type="doi">10.1007/s00213-013-3408-y</pub-id><pub-id pub-id-type="pmid">24408210</pub-id></element-citation></ref><ref id="CR18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jongen</surname><given-names>S</given-names></name><name><surname>Perrier</surname><given-names>J</given-names></name><name><surname>Vuurman</surname><given-names>EF</given-names></name><name><surname>Ramaekers</surname><given-names>JG</given-names></name><name><surname>Vermeeren</surname><given-names>A</given-names></name></person-group><article-title>Sensitivity and validity of psychometric tests for assessing driving impairment: effects of sleep deprivation</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><issue>2</issue><fpage>e0117045</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0117045</pub-id><pub-id pub-id-type="pmid">25668292</pub-id></element-citation></ref><ref id="CR19"><mixed-citation publication-type="other">Kay, G. G., &#x00026; Logan, B. K. (2011). Drugged driving expert panel report: a consensus protocol for assessing the potential of drugs to impair driving (no. HS-811 438)</mixed-citation></ref><ref id="CR20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleykamp</surname><given-names>BA</given-names></name><name><surname>Griffiths</surname><given-names>RR</given-names></name><name><surname>Mintzer</surname><given-names>MZ</given-names></name></person-group><article-title>Dose effects of triazolam and alcohol on cognitive performance in healthy volunteers</article-title><source>Exp Clin Psychopharmacol</source><year>2010</year><volume>18</volume><issue>1</issue><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1037/a0018407</pub-id><pub-id pub-id-type="pmid">20158290</pub-id></element-citation></ref><ref id="CR21"><mixed-citation publication-type="other">Lakens D (2013) Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs. Front Psychol 4(863). 10.3389/fpsyg.2013.00863</mixed-citation></ref><ref id="CR22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leufkens</surname><given-names>TRM</given-names></name><name><surname>Vermeeren</surname><given-names>A</given-names></name></person-group><article-title>Zopiclone&#x02019;s residual effects on actual driving performance in a standardized test: a pooled analysis of age and sex effects in 4 placebo-controlled studies</article-title><source>Clin Ther</source><year>2014</year><volume>36</volume><issue>1</issue><fpage>141</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2013.11.005</pub-id><pub-id pub-id-type="pmid">24360801</pub-id></element-citation></ref><ref id="CR23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leufkens</surname><given-names>TRM</given-names></name><name><surname>Vermeeren</surname><given-names>A</given-names></name><name><surname>Smink</surname><given-names>BE</given-names></name><name><surname>van Ruitenbeek</surname><given-names>P</given-names></name><name><surname>Ramaekers</surname><given-names>JG</given-names></name></person-group><article-title>Cognitive, psychomotor and actual driving performance in healthy volunteers after immediate and extended release formulations of alprazolam 1 mg</article-title><source>Psychopharmacology</source><year>2007</year><volume>191</volume><issue>4</issue><fpage>951</fpage><lpage>959</lpage><pub-id pub-id-type="doi">10.1007/s00213-006-0669-8</pub-id><pub-id pub-id-type="pmid">17219217</pub-id></element-citation></ref><ref id="CR24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leufkens</surname><given-names>TRM</given-names></name><name><surname>Lund</surname><given-names>JS</given-names></name><name><surname>Vermeeren</surname><given-names>A</given-names></name></person-group><article-title>Highway driving performance and cognitive functioning the morning after bedtime and middle-of-the-night use of gaboxadol, zopiclone and zolpidem</article-title><source>J Sleep Res</source><year>2009</year><volume>18</volume><issue>4</issue><fpage>387</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2869.2009.00746.x</pub-id><pub-id pub-id-type="pmid">19552733</pub-id></element-citation></ref><ref id="CR25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leufkens</surname><given-names>TRM</given-names></name><name><surname>Ramaekers</surname><given-names>JG</given-names></name><name><surname>de Weerd</surname><given-names>AW</given-names></name><name><surname>Riedel</surname><given-names>WJ</given-names></name><name><surname>Vermeeren</surname><given-names>A</given-names></name></person-group><article-title>Residual effects of zopiclone 7.5 mg on highway driving performance in insomnia patients and healthy controls: a placebo controlled crossover study</article-title><source>Psychopharmacology</source><year>2014</year><volume>231</volume><issue>14</issue><fpage>2785</fpage><lpage>2798</lpage><pub-id pub-id-type="pmid">24458443</pub-id></element-citation></ref><ref id="CR26"><mixed-citation publication-type="other">Louwerens J, Gloerich A, de Vries G, Brookhuis K, O&#x02019;Hanlon J (1987) The relationship between drivers&#x02019; blood alcohol concentration (BAC) and actual driving performance during high speed travel. In: Noordzij PC, Roszbach R (eds) Alcohol drugs traffic safety. T86 Elsevier, Amsterdam, pp 183&#x02013;186</mixed-citation></ref><ref id="CR27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLeod</surname><given-names>DR</given-names></name><name><surname>Griffiths</surname><given-names>RR</given-names></name><name><surname>Bigelow</surname><given-names>GE</given-names></name><name><surname>Yingling</surname><given-names>J</given-names></name></person-group><article-title>An automated version of the digit symbol substitution test (DSST)</article-title><source>Behav Res Methods Instrum</source><year>1982</year><volume>14</volume><issue>5</issue><fpage>463</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.3758/BF03203313</pub-id></element-citation></ref><ref id="CR28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michon</surname><given-names>JA</given-names></name></person-group><article-title>Explanatory pitfalls and rule-based driver models</article-title><source>Accid Anal Prev</source><year>1989</year><volume>21</volume><issue>4</issue><fpage>341</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1016/0001-4575(89)90025-0</pub-id><pub-id pub-id-type="pmid">2669785</pub-id></element-citation></ref><ref id="CR29"><mixed-citation publication-type="other">Moskowitz, H. (1973). Laboratory studies of the effects of alcohol on some variables related to driving. Journal of Safety Research</mixed-citation></ref><ref id="CR30"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Mulder-Hajonides van der Meulen</surname><given-names>WREH</given-names></name><name><surname>Wijnberg</surname><given-names>JR</given-names></name><name><surname>Hollander</surname><given-names>JJ</given-names></name><name><surname>De Diana</surname><given-names>IPF</given-names></name><name><surname>Van den Hoofdakker</surname><given-names>RH</given-names></name></person-group><source>Measurement of subjective sleep quality. In Proceedings of the International European Sleep Congress</source><year>1981</year><publisher-loc>Amsterdam</publisher-loc><publisher-name>Elsevier</publisher-name></element-citation></ref><ref id="CR31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neutel</surname><given-names>CI</given-names></name></person-group><article-title>Risk of traffic accident injury after a prescription for a benzodiazepine</article-title><source>Ann Epidemiol</source><year>1995</year><volume>5</volume><issue>3</issue><fpage>239</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1016/1047-2797(94)00112-7</pub-id><pub-id pub-id-type="pmid">7606314</pub-id></element-citation></ref><ref id="CR32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Hanlon</surname><given-names>JF</given-names></name></person-group><article-title>Driving performance under the influence of drugs: rationale for, and application of, a new test</article-title><source>Br J Clin Pharmacol</source><year>1984</year><volume>18</volume><issue>Suppl 1</issue><fpage>121S</fpage><lpage>129S</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.1984.tb02590.x</pub-id><pub-id pub-id-type="pmid">6525328</pub-id></element-citation></ref><ref id="CR33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Hanlon</surname><given-names>JF</given-names></name><name><surname>Ramaekers</surname><given-names>JG</given-names></name></person-group><article-title>Antihistamine effects on actual driving performance in a standard test: a summary of Dutch experience, 1989-94</article-title><source>Allergy</source><year>1995</year><volume>50</volume><issue>3</issue><fpage>234</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1111/j.1398-9995.1995.tb01140.x</pub-id><pub-id pub-id-type="pmid">7677241</pub-id></element-citation></ref><ref id="CR34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Hanlon</surname><given-names>JF</given-names></name><name><surname>Haak</surname><given-names>TW</given-names></name><name><surname>Blaauw</surname><given-names>GJ</given-names></name><name><surname>Riemersma</surname><given-names>JB</given-names></name></person-group><article-title>Diazepam impairs lateral position control in highway driving</article-title><source>Science</source><year>1982</year><volume>217</volume><issue>4554</issue><fpage>79</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1126/science.7089544</pub-id><pub-id pub-id-type="pmid">7089544</pub-id></element-citation></ref><ref id="CR35"><mixed-citation publication-type="other">O&#x02019;Hanlon JF, Brookhuis KA, Louwerens JW, Volkerts ER (1986) Performance testing as part of drug registration. Drugs Driving:311&#x02013;320</mixed-citation></ref><ref id="CR36"><mixed-citation publication-type="other">Owens, K., &#x00026; Ramaekers, J. G. (2009). Drugs, driving, and models to measure driving impairment. In Drugs, driving and traffic safety (pp. 43-58). Birkh&#x000e4;user Basel</mixed-citation></ref><ref id="CR37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramaekers</surname><given-names>JG</given-names></name></person-group><article-title>Antidepressants and driver impairment: empirical evidence from a standard on-the-road test</article-title><source>J Clin Psychiatry</source><year>2003</year><volume>64</volume><issue>1</issue><fpage>20</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.4088/JCP.v64n0106</pub-id><pub-id pub-id-type="pmid">12590619</pub-id></element-citation></ref><ref id="CR38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ray</surname><given-names>WA</given-names></name><name><surname>Fought</surname><given-names>RL</given-names></name><name><surname>Decker</surname><given-names>MD</given-names></name></person-group><article-title>Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers</article-title><source>Am J Epidemiol</source><year>1992</year><volume>136</volume><issue>7</issue><fpage>873</fpage><lpage>883</lpage><pub-id pub-id-type="doi">10.1093/aje/136.7.873</pub-id><pub-id pub-id-type="pmid">1442753</pub-id></element-citation></ref><ref id="CR39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robbe</surname><given-names>HW</given-names></name><name><surname>O'Hanlon</surname><given-names>JF</given-names></name></person-group><article-title>Acute and subchronic effects of paroxetine 20 and 40 mg on actual driving, psychomotor performance and subjective assessments in healthy volunteers</article-title><source>Eur Neuropsychopharmacol</source><year>1995</year><volume>5</volume><issue>1</issue><fpage>35</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/0924-977X(94)00130-4</pub-id><pub-id pub-id-type="pmid">7613099</pub-id></element-citation></ref><ref id="CR40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>T</given-names></name><name><surname>Eklov</surname><given-names>SD</given-names></name><name><surname>Drake</surname><given-names>CL</given-names></name><name><surname>Verster</surname><given-names>JC</given-names></name></person-group><article-title>Meta-analysis of on-the-road experimental studies of hypnotics: effects of time after intake, dose, and half-life</article-title><source>Traffic Inj Prev</source><year>2014</year><volume>15</volume><issue>5</issue><fpage>439</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1080/15389588.2013.830211</pub-id><pub-id pub-id-type="pmid">24678565</pub-id></element-citation></ref><ref id="CR41"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Schuhfried</surname><given-names>G</given-names></name></person-group><source>Manual expert system traffic (XPSV)</source><year>2005</year><publisher-loc>M&#x000f6;dling</publisher-loc><publisher-name>SCHUHFRIED GmbH</publisher-name></element-citation></ref><ref id="CR42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seppala</surname><given-names>T</given-names></name><name><surname>Linnoila</surname><given-names>M</given-names></name><name><surname>Mattila</surname><given-names>MJ</given-names></name></person-group><article-title>Drugs, alcohol and driving</article-title><source>Drugs</source><year>1979</year><volume>17</volume><issue>5</issue><fpage>389</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.2165/00003495-197917050-00008</pub-id><pub-id pub-id-type="pmid">37067</pub-id></element-citation></ref><ref id="CR43"><mixed-citation publication-type="other">van der Sluiszen NNJJM, Vermeeren A, Jongen S, Vinckenbosch F, Ramaekers JG (2017) Influence of long-term benzodiazepine use on neurocognitive skills related to driving performance in patient populations: a review. Pharmacopsychiatry. 10.1055/s-0043-112755</mixed-citation></ref><ref id="CR44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiplady</surname><given-names>B</given-names></name><name><surname>Hiroz</surname><given-names>J</given-names></name><name><surname>Holmes</surname><given-names>L</given-names></name><name><surname>Drummond</surname><given-names>G</given-names></name></person-group><article-title>Errors in performance testing: a comparison of ethanol and temazepam</article-title><source>J Psychopharmacol</source><year>2003</year><volume>17</volume><issue>1</issue><fpage>41</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1177/0269881103017001691</pub-id><pub-id pub-id-type="pmid">12680738</pub-id></element-citation></ref><ref id="CR45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vermeeren</surname><given-names>A</given-names></name></person-group><article-title>Residual effects of hypnotics: epidemiology and clinical implications</article-title><source>CNS Drugs</source><year>2004</year><volume>18</volume><issue>5</issue><fpage>297</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.2165/00023210-200418050-00003</pub-id><pub-id pub-id-type="pmid">15089115</pub-id></element-citation></ref><ref id="CR46"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Vermeeren</surname><given-names>A</given-names></name><name><surname>Gier</surname><given-names>JJ</given-names></name><name><surname>O'Hanlon</surname><given-names>JF</given-names></name></person-group><source>Methodological guidelines for experimental research on medicinal drugs affecting driving performance: an international expert survey</source><year>1993</year><publisher-loc>Institute for Human Psychopharmacology</publisher-loc><publisher-name>University of Limburg</publisher-name></element-citation></ref><ref id="CR47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vermeeren</surname><given-names>A</given-names></name><name><surname>Riedel</surname><given-names>WJ</given-names></name><name><surname>van Boxtel</surname><given-names>MPJ</given-names></name><name><surname>Darwish</surname><given-names>M</given-names></name><name><surname>Paty</surname><given-names>I</given-names></name><name><surname>Patat</surname><given-names>A</given-names></name></person-group><article-title>Differential residual effects of zaleplon and zopiclone on actual driving: a comparison with a low dose of alcohol</article-title><source>Sleep</source><year>2002</year><volume>25</volume><issue>2</issue><fpage>224</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">11905433</pub-id></element-citation></ref><ref id="CR48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verster</surname><given-names>JC</given-names></name><name><surname>Roth</surname><given-names>T</given-names></name></person-group><article-title>Standard operation procedures for conducting the on-the-road driving test, and measurement of the standard deviation of lateral position (SDLP)</article-title><source>Int J Gen Med</source><year>2011</year><volume>4</volume><fpage>359</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.2147/IJGM.S19639</pub-id><pub-id pub-id-type="pmid">21625472</pub-id></element-citation></ref><ref id="CR49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verster</surname><given-names>JC</given-names></name><name><surname>Roth</surname><given-names>T</given-names></name></person-group><article-title>Predicting psychopharmacological drug effects on actual driving performance (SDLP) from psychometric tests measuring driving-related skills</article-title><source>Psychopharmacology</source><year>2012</year><volume>220</volume><issue>2</issue><fpage>293</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1007/s00213-011-2484-0</pub-id><pub-id pub-id-type="pmid">21922169</pub-id></element-citation></ref><ref id="CR50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vuurman</surname><given-names>EFPM</given-names></name><name><surname>Rikken</surname><given-names>GH</given-names></name><name><surname>Muntjewerff</surname><given-names>ND</given-names></name><name><surname>de Halleux</surname><given-names>F</given-names></name><name><surname>Ramaekers</surname><given-names>JG</given-names></name></person-group><article-title>Effects of desloratadine, diphenhydramine, and placebo on driving performance and psychomotor performance measurements</article-title><source>Eur J Clin Pharmacol</source><year>2004</year><volume>60</volume><issue>5</issue><fpage>307</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1007/s00228-004-0757-9</pub-id><pub-id pub-id-type="pmid">15168099</pub-id></element-citation></ref><ref id="CR51"><mixed-citation publication-type="other">Walsh JM, Verstraete AG, Huestis, M. a, &#x00026; M&#x000f8;rland, J. (2008) Guidelines for research on drugged driving. Addiction 103(8):1258&#x02013;1268. 10.1111/j.1360-0443.2008.02277</mixed-citation></ref></ref-list></back></article>